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Abstract
Background Few studies have examined the risk of computed
tomography angiography (CTA) during the acute phase of
spontaneous intracerebral hemorrhage (ICH), while the bene-
fits of CTA in ICH have been well-documented. The present
study investigated both the benefits of identifying spot signs,
which are supposed to indicate hematoma enlargement after
admission, and risks of CTA performed during the acute phase
of ICH.
Methods We retrospectively assessed 323 consecutive pa-
tients with spontaneous ICHs admitted to our hospital be-
tween April 2009 and March 2012 and who underwent CTA
on admission.
Results In 80 patients (24.7 %), spot signs were demonstrated
on CTA source images. Multivariate analysis revealed two
independent factors correlated with presence of the spot sign:
age and hematoma volume (p<0.05 each). The presence of
spot sign was associated with unfavorable outcomes at dis-
charge and hematoma growth after admission (p<0.05 each).
Adverse events related to CTA occurred in 17 patients
(5.2 %), including transient renal dysfunction in 16 patients
and allergy to contrast medium in one patient. All adverse
events completely resolved within 1 week.
Conclusions Presence of the spot sign indicated the possibil-
ity of hematoma growth and unfavorable outcomes. A small
number of adverse events occurred in association with CTA,
but without any permanent deficits. Given the potential
benefits and risks, we believe that CTA performed at admis-
sion in all patients with ICH is beneficial to improve the
outcomes.
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Introduction
Intracerebral hemorrhage (ICH) has a more unfavorable
outcome than ischemic stroke in terms of the grade of
poststroke disability and mortality rate [1, 4]. Hematoma
expansion has been identified as one of the most important
determinants of early neurological deterioration and unfa-
vorable clinical outcome [5, 6]. The spot sign is a high-
density area of contrast media leakage within the hematoma
on a source image from computed tomography angiography
(CTA) performed in the acute stage of ICH. Several studies
have reported that the presence of spot sign predicts hema-
toma growth [7, 8, 14]. Patients with the spot sign may be
candidates for management with intensive blood pressure
(BP)-lowering or hemostatic therapies. Although CTA has
possible side effects due to the bolus injection of contrast
media, such as on renal function and/or allergy to contrast
medium, few studies have reported on the risks of CTA
during acute-stage ICH [13, 16, 22].
The present study first investigated predictive factors for
occurrence of the spot sign in patients with ICH undertaking
CTA immediately after admission. We then evaluated rela-
tionships between the spot sign and outcomes. Finally, we
examined the risk of CTA performed immediately after the
onset of ICH.
This study was presented at the Annual Meeting of the Japanese
Neurosurgical Society 2012 held in Tokyo.
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We retrospectively assessed consecutive patients with sponta-
neous ICH admitted to our hospital between April 2009 and
March 2012. Patients admitted later than 24 h after onset were
excluded. This series of patients did not include those with
secondary ICH caused by cerebral aneurysm, vascular mal-
formation, moyamoya disease or trauma. Patients who did not
undertake CTA on admission were excluded. Patients present-
ing with hemorrhagic stroke admitted to our neurosurgical
unit routinely underwent the first non-contrast CT on arrival,
followed by a CTA study, unless a history of renal dysfunction
and/or allergic history to contrast agent was obtained. Emer-
gency hematoma removal was performed in patients less than
80 years old with severe disturbance of consciousness due to
mass effect of the hematoma or with impending tentorial
herniation due to the hematoma. Ventricular drainage was
performed in patients with acute hydrocephalus on non-
contrast CT. The study was approved by the ethics committee
at Tokai University School of Medicine.
Image acquisition
The CT protocol was performed on a 40 slice CT (Brilliance;
PHILIPS, Best, the Netherlands). Pre-contrast head imaging
was acquired from the skull base to the vertex under the
following parameters: collimation, 40×0.625 mm; 120 kVp;
450mA; rotation time, 1 s/rotation tube, at table speed 15mm/
rotation. CTAwas performed from the C4 cervical level to the
vertex under the following parameters: collimation, 40×
0.625 mm; 120 kVp; 370 mA; rotation time, 0.5 s/rotation;
table speed, 15 mm/rotation. The CTA protocol was per-
formed using a bolus tracking method in which non-ionic
contrast agent (iohexol or iopamidol) was injected at 4 ml/s
through a peripheral vein via an indwelling 20-G
angiocatheter. Pre-contrast images were reconstituted as axial,
5-mm-thick images. Three-dimensional CTA images were
reconstituted as axial and coronal, 3-mm-thick images. All
images were viewed on the software of a computer terminal.
Image analysis
All studies were evaluated by 10 neurosurgeons separately for
the presence or absence of spot signs by simultaneously
visualizing non-contrast CT studies cross-linked with coronal
axial CTA reformats. Spot sign was defined as an enhancing
focus >1mm in diameter within a hematoma on a CTA source
image. Maximum attenuation was defined as more than twice
the Hounsfield unit (HU) value of the surrounding hematoma,
or >120 HU [24]. A consensus reading by several neurosur-
geons was conducted to resolve any ambiguous findings
regarding the interpretation of CTA source images. Hematoma
volume was calculated using the ABC/2 method [15]. Pre-
contrast CT was performed on admission and on the second
day after admission. Hematoma growth was defined as a
volume increase of ≥12.5 ml or ≥33% [24].
Data collection
Clinical data were obtained through chart review. The follow-
ing data were recorded: patient age and sex, level of con-
sciousness (Glasgow coma scale [GCS] score) on admission,
systolic BP on admission, use of antiplatelet agents, use of
anticoagulants, and time from ICH onset to admission. Clin-
ical outcomes were assessed using the modified Rankin Scale
(mRS) score at discharge. Favorable and unfavorable out-
comes were defined as mRS 0–2 and 3–6, respectively.
Acute renal dysfunction, allergic symptoms, and anaphy-
lactic reactions to contrast medium were investigated as com-
plications caused by CTA. In all patients, serum creatinine
(Cr) levels were examined for three consecutive days after
admission. Renal dysfunction, based on the definition of the
Radiological European Society of Urogenital Radiology [21],
was defined as a ≥25% increase over the reference value, or an
increase of >0.5 mg/dl in serum creatinine within 3 days of
exposure to the contrast media. The occurrence of clinical
signs of hypotension, nausea, vomiting, urticaria, or pruritus
after CTAwas investigated as potential anaphylactic reactions
or allergic symptoms.
Statistical analysis
Univariate analysis was performed using chi-squared analysis
and Fisher’s exact probability test for categorical variables and
using one-way analysis of variance for continuous variables.
Numerical data are expressed as the mean ± standard
deviation.
Each variable was analyzed using univariate analysis to
identify possible significant predictors; those variables found
to be possibly significant at the p<0.10 level were then
included in multivariate logistic regression analysis, which
was reduced by successively removing the least significant
variable from the model. All variables showing a value of
p<0.10 were kept in the final model. Analyses resulting in
values of p<0.05 were considered statistically significant. All
statistical analyses were performed using of JMP version 10
software (SAS Institute, Cary, NC, USA).
Results
Between April 2009 and March 2013, we treated 568 consec-
utive patients diagnosed with spontaneous ICH. Of the 568
patients, 15 admitted >24 h after onset and 230 who failed to
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undergo CTA on admission were excluded. A total of 323
patients met the inclusion criteria of the study, with a mean age
of 67.0±13.0 years. Hematomas were present in the putamen
in 105 patients (32.5 %), thalamus in 71 (29.2 %), both
putamen and thalamus in 12 (4.9 %), cortex in 35 (14.4 %),
subcortex in 28 (11.5 %), cerebellum in 35 (14.4 %),
brainstem in 12 (4.9 %), and caudate nucleus in 11 (4.5 %).
External ventricular drainage or hematoma removal was per-
formed in 12 and 87 patients, respectively.
In 80 of the 323 patients (24.7 %) who underwent CTA,
spot signs were demonstrated on CTA source images. Table 1
shows the following factors for patients with and without spot
sign: age, sex, use of antiplatelet agents, hematoma location,
time from symptom onset to admission, level of conscious-
ness (GCS score) on admission, systolic BP on admission,
hematoma volume, and presence of intraventricular hemor-
rhage. In univariate analyses, significant differences were
found in age and hematoma volume between spot sign-
positive and -negative groups. Multivariate analysis revealed
two independent factors correlated with presence of spot sign:
age (p=0.0160; odds ratio [OR], 1.030) and hematoma vol-
ume (p=0.0063; OR, 1.006).







OR (95 % CI) P value
Multivariate analysis
Age (years) 71.1±12.0 66.2±12.7 0.0014 1.030 (1.009–1.054) 0.0160
Use of antiplatelet drugs 17 38 0.2467
Male 51 136 0.2214
Putamen 26 79 0.9986
Thalamus 20 51 0.4523
Brain stem 4 8 0.4836
Cortex 17 58 0.6516
Caudate head 0 11 0.0717
Cerebrum 8 27 0.7815
Time from onset to admission (min) 208.261±705.856 288.919±788.732 0.7747
GCS<8 at admission 28 63 0.1176
SBP at admission (mmHg) 183.986±30.3922 181.539±40.5162 0.3127
Hematoma volume (cm3) 54326.9±47330.3 36583.6±49927.9 0.0028 1.006 (1.001–1.011) 0.0063
Intraventricular hemorrhage 44 117 0.3492
GCS Glasgow Coma Scale; SBP systolic blood pressure
Fig. 1 A relationship between
age and hematoma volume,
which are independent predictors
for spot signs, and presence of
spot signs. No clear cutoff value
of age or hematoma volume for
presence of spot signs is
demonstrated. A black circle
indicates a patient with spot signs,
and a white circle a patient
without spot signs
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Figure 1 shows a relationship between age and hematoma
volume, which were the independent predictors for spot signs,
and presence of spot signs. This graph does not show any
apparent cut-off value of age or hematoma volume for pres-
ence of spot signs.
Table 2 shows the relationship between presence of spot
sign and hematoma growth on CT on the day after onset.
Patients, who underwent emergency hematoma removal,
comprising 33 patients with spot sign and 54 without spot
sign, were excluded, because follow-up CT could not be
performed for evaluation of hematoma growth. Hematoma
enlargement was found on CT the day after admission in 15
of 40 patients (37.5 %) with spot sign and in 14 of 158 (8.9 %)
without spot sign. The frequency of hematoma enlargement
was significantly larger in patients with spot sign than in
patients without spot sign (p<0.0001).
Figure 2 demonstrates the relationship between presence of
spot sign and outcome. Favorable outcomes, defined as
mRS≤2 at discharge, were obtained four 4 of 80 patients
(5.0 %) with spot sign, and 37 of 243 (15.2 %) without spot
sign. The frequency of favorable outcomes was significantly
smaller in patients with spot sign than those without (p=
0.0158). Death occurred in 17 of 80 patients (21.3 %) with
spot sign and 28 of 243 patients (11.5 %) without spot sign,
and was thus significantly more frequent with the spot sign
(p=0.0327). Relationships between spot sign and out-
come were re-examined separately in patients with he-
matoma volume ≥50 ml and in patients with hematoma
volume <50 ml, since hematoma volume strongly influ-
ences outcome (Table 3). In patients with hematoma
volume <50 ml, the frequency of unfavorable outcomes
was significantly larger in patients with spot sign than
in patients without spot sign (p=0.01149). On the other
hand, in the group with hematoma volume ≥50 ml, no
significant difference in outcome was apparent between
patients with and without spot sign.
Adverse events of CTA occurred in 17 of 323 patients
(5.2 %), comprising transient renal dysfunction in 16 patients
and allergy to contrast media in 1 patient. No other complica-
tions related to CTAwere encountered. Figure 3 demonstrates
the time course of Cr levels in the 16 patients with renal
dysfunction. In all these patients, Cr levels normalized within
1 week without any aggressive treatment, including dialysis.
The patient who suffered from allergic reaction to contrast
media showed hypotension immediately after administration
of the contrast media for less than 10 min. Symptoms im-
proved from 5 h after onset with hydration and administration
of antihistamine.
Discussion
The present study identified patient age and hematoma vol-
ume as predictors for occurrence of the spot sign. Progression
Table 2 Relationships between spot sign occurrence and hematoma
enlargement
Spot sign
Positive (n=80) Negative (n=238)
Hematoma enlargement 15 14
Hematoma stable 25 144
Not availablea 40 80
aNot available = CT was not performed the day following admission
because of hematoma removal, death, or other reasons
Fig. 2 Outcomes for patients with spontaneous intracerebral hemorrhage with or without spot signs. Favorable outcome (mRS 0-2) was significantly
less frequent in patients with spot signs than in patients without spot signs
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of arteriosclerotic changes in the perforating arteries, which
are etiological arteries for ICH, was considered to result in the
more frequent observation of spot sign in older patients com-
pared with the younger patients [9, 23]. Increased vulnerabil-
ity to rupture of arteries in the arteriosclerotic perforating
arteries could prevent hemostasis after the onset of ICH. Large
hematoma volume, another predictor of spot sign, might be
the result of ongoing bleeding expressed as the spot sign. In
previous studies, several factors including hematoma volume,
GCS, time from onset to admission, blood glucose level
>170 mg/dl, mean BP on admission >120 mmHg, higher
prothrombin time (PT)-INR, and use of antiplatelet agents
and anticoagulants has been reported as a predictor for spot
sign [3, 24]. The present study revealed age as a predictor for
spot sign, a finding that has not been reported previously. The
large number of patients that participated in this study might
have facilitated the detection of this previously unrevealed
finding. Compared with Western populations, the Japanese
prevalence of ICH might explain the different result between
the present study and previous investigations. Our study
showed no apparent cut-off value of age or hematoma volume
for presence of spot signs. So age and hematoma volume
could not be used as indicators to perform CTA.
The significantly larger frequency of hematoma enlarge-
ment in the group with positive spot sign demonstrated in this
study resembled the results of previous reports [7, 8, 12, 14].
The spot sign was considered to indicate ongoing bleeding
from the perforating arteries, which resulted in hematoma
enlargement. In consideration of the hematoma expansion
observed in patients without spot sign, other possible mecha-
nisms of hematoma expansion may include oozing of blood
from arteries and/or veins, which failed to show the spot sign,
and intermittent bleeding from arteries.
In patients with hematoma volume <50 ml in this study, the
frequency of unfavorable outcomes was significantly higher
in patients with spot sign compared to those without spot sign.
On the other hand, among those patients in whom hematoma
volume was ≥50 ml, no significant differences in outcome
Table 3 Relationships among hematoma volume, presence of spot sign and outcome
Hematoma volume
<50 ml (n=224) Spot sign ≥50 ml (n=96) Spot sign
Positive (n=47) Negative (n=177) Positive (n=33) Negative (n=63)
mRS 0–2 3 (6.4 %) 34 (19.2 %) 1 (3.0 %) 3 (4.7 %)
3–6 44 (93.6 %) 143 (80.8 %) 32 (97.0 %) 60 (95.2 %)
Three patients, in which the hematoma volume value was not available, were excluded
Fig. 3 Changes of serum creatinine levels in patients suffering from contrast medium-induced nephropathy. All 12 patients in renal failure after
admission show improvement of serum creatinine levels to the previous level within 7 days
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were observed between groups with and without spot sign.
Hematoma volume is a well-known predictor of unfavorable
outcomes, as well as a predictor for the presence of spot sign
[7, 8, 14].We investigated relationships between spot sign and
outcome separately in patients with hematoma volume ≥50ml
and <50 ml, because hematoma volume is a possible con-
founding factor for both spot sign and outcome. In ICH
showing both spot sign and hematoma volume <50 ml, ther-
apeutic intervention aimed at preventing hematoma expan-
sion, including strict blood pressure control and hemostatic
agents, could be considered.
Several randomized control trials have been recently con-
ducted to clarify an effect of aggressive medical treatment or
emergency surgery on outcomes in patients with spontaneous
ICHs. The Intensive Blood Pressure Reduction in Acute Ce-
rebral Hemorrhage Trial 2 (INTERACT2), which is a random-
ized control trial to test an effect of blood pressure lowering on
outcomes in ICH patients, showed intensive lowering of blood
pressure with a target systolic level of <140 mm Hg within 1 h
improved functional outcomes in comparison to American
Stroke Association guidelines-recommended treatment
with a target systolic level of 180 mm Hg [2]. Two phase
II trials of rFVIIa in ICH patients using spot sign selection
are underway in Canada and the United states [10, 11],
though improvement in survival and functional outcomes
by use of rFVIIa were not found in a large phase III ran-
domized control trial without spot sign selection [17, 18].
An examination of spot sign and tranexamic acid on
preventing ICH growth, which is a phase II randomized
control trial, is also ongoing in Australia [20]. Identification
of spot sign in ICH becomes more important if the results of
these trials show improvement of outcomes in the aggres-
sive medical treatment group in the future.
Spontaneous supratentorial lobar intracerebral hematomas
(STICH II) trial, which was a randomized control trial to
investigate an effect of early surgery on outcomes in patients
with superficial lobar intracerebral hemorrhage, did not show
significant evidence to support the benefit of early surgery
[19]. In our study, emergency surgery was performed in
patients showing herniation sign to save their lives and not
to improve their functional outcomes. We believe that strict
blood pressure control, careful observation of the neurological
status, and preparation of emergency surgery to save life
should be performed during the first 24 h in patients showing
spot signs.
The present study demonstrated that adverse events
associated with CTA occurred in 5.2 % of patients,
consisting of acute renal dysfunction in 4.9 % and allergic
reaction in 0.3 %. In all patients, acute renal dysfunction
resolved completely within 1 week. No residual impair-
ment related to CTA was shown in this series. The bolus
injection of contrast media used for CTA can result in more
serious side effects compared with usual contrast CT. In
addition, CTA was performed immediately after arrival in
the emergency department, so a detailed history of renal
function could not be obtained, and laboratory data related
to renal function could not be obtained prior to CTA.
Studies into the adverse effects of CTA on renal function
in the acute stage of ICH are scarce. One such study
reported that renal dysfunction occurred transiently, if
present [22]. For the prevention of renal dysfunction, in-
fusion of a sufficient volume of fluid should be performed
after CTA, especially in the acute stage of ICH. An effort to
elicit the history of renal function should be made on
admission. According to the attached document of iohexol,
hypotension after injection of the contrast medium oc-
curred in 28 of 18,657 cases (0.15 %). The frequency of
hypotensive reaction to contrast medium in the present
study was similar to the reported rate.
Conclusions
In this study, spot sign on a CTA source image was demon-
strated in 80 of 223 patients (24.6 %) with acute ICH. Predic-
tors for the presence of spot sign were age and initial hema-
toma volume on CT. In patients with hematoma <50 ml,
outcomes were significantly worse in patients with spot
sign than in those without. A CTA study of acute ICH
cases could elucidate the etiologies of secondary ICH as
well as predict outcomes in primary ICH. No permanent
complications related to CTA occurred in the acute
stage of ICH. We believe that CTA performed at admis-
sion in all patients with ICH is beneficial to improve
the outcomes in consideration of both the benefit and
risk of CTA demonstrated in the present study.
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